Recombinant Mouse LILRA6/CD85b/ILT8 Fc Chimera Protein, CF

When Recombinant Human Angiopoietin-like 7 (Catalog # 914-AN) is coated at 2 µg/mL, Recombinant Mouse LILRA6/CD85b/ILT8 Fc Chimera (Catalog # 9320-T4) binds with anED50 = 5-30 ng/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse LILRA6/CD85b/ILT8 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) is coated at 2 µg/mL, Recombinant Mouse LILRA6/CD85b Fc Chimera binds with an ED₅₀ = 5-30 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse LILRA6/CD85b protein
  

  Mouse LILRA6/CD85b/ILT8 (Gly24-Asn629) Accession # NP_035220	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: NP_035220
• N-terminal Sequence: Gly24
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 95 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 97-118 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MES and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse LILRA6/CD85b/ILT8 Fc Chimera Protein, CF

• 7M1
• CD85b
• CD85b;ILT5;ILT8;ILT-8;LILRB3;LILRB6
• ILT8
• LILRA6
• Pira3

Background

LILRA6, also known as ILT8, CD85b, and PIR-A3 (in mouse), is a transmembrane molecule that belongs to the LILR family of immune regulatory proteins (1, 2). LILRA family members augment immune responses, while LILRB proteins inhibit signaling events (3). The extracellular region (ECD) of mouse LILRA6/PIR-A3 contains 6 immunoglobulin-like domains in its extracellular region, although the human protein contains four Ig-like domains. Within common regions of their ECDs, human LILRA6 shares 53% amino acid sequence identity with mouse PIR-A3. It contains a positively charged arginine residue in the transmembrane segment which mediates association with the signaling protein Fc epsilon RI gamma (4). LILRA6 is primarily expressed on monocytes (5). Its gene copy number is highly variable and is positively associated with the development of atopic dermatitis (2, 6). Allelic polymorphisms are differentially able to mediate immune cell detection of necrotic cells (7, 8). R&D Systems in-house testing indicates that LILRA6 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (9).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Hirayasu, K. and H. Arase (2015) J. Hum. Genet. 60:703.
3. Anderson, K.J. and R.L. Allen (2009) Immunology 127:8.
4. Taylor, L.S. and D.W. McVicar (1999) 94:1790.
5. Bashirova, A.A. et al. (2014) Immunogenetics 66:1.
6. Lopez-Alvarez, M.R. et al. (2016) Immunogenetics 68:743.
7. Jones, D.C. et al. (2016) Oncotarget 7:15618.
8. Lopez-Alvarez, M.R. et al. (2014) Immunogenetics 66:73.
9. Zheng, J. et al. (2012) Nature 485:656.

Bioinformatics

• Uniprot:
  • NP_035220()